VE11 Stock Overview
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aravive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.039 |
| 52 Week High | US$1.87 |
| 52 Week Low | US$0.035 |
| Beta | 2.19 |
| 1 Month Change | -64.86% |
| 3 Month Change | -69.29% |
| 1 Year Change | n/a |
| 3 Year Change | -99.07% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| VE11 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | -0.8% | -1.6% |
| 1Y | n/a | -13.0% | 6.8% |
Return vs Industry: Insufficient data to determine how VE11 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how VE11 performed against the German Market.
Price Volatility
| VE11 volatility | |
|---|---|
| VE11 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VE11's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VE11's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 23 | n/a | aravive.com |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.
Aravive, Inc. Fundamentals Summary
| VE11 fundamental statistics | |
|---|---|
| Market cap | €2.73m |
| Earnings (TTM) | -€36.83m |
| Revenue (TTM) | €6.46m |
0.4x
P/S Ratio-0.1x
P/E RatioIs VE11 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VE11 income statement (TTM) | |
|---|---|
| Revenue | US$6.99m |
| Cost of Revenue | US$53.39m |
| Gross Profit | -US$46.39m |
| Other Expenses | -US$6.55m |
| Earnings | -US$39.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -663.34% |
| Net Profit Margin | -569.73% |
| Debt/Equity Ratio | 0% |
How did VE11 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/29 08:53 |
| End of Day Share Price | 2024/01/29 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aravive, Inc. is covered by 16 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BTIG |
| John Newman | Canaccord Genuity |
| Louise Chen | Cantor Fitzgerald & Co. |